High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
266.60M
-10.78%
0.740
-22.11%
283.17M
-0.29%
0.900
-9.09%
375.30M
+2.79%
1.590
+14.39%
Estimates Revision
The market is revising Downward the revenue expectations for Ingevity Corporation (NGVT) for FY2025, with the revenue forecasts being adjusted by -0.66% over the past three months. During the same period, the stock price has changed by -12.58%.
Revenue Estimates for FY2025
Revise Downward
-0.66%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+5.16%
In Past 3 Month
Stock Price
Go Down
-12.58%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast NGVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NGVT is 62.00 USD with a low forecast of 55.00 USD and a high forecast of 69.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 52.250
Low
55.00
Averages
62.00
High
69.00
Current: 52.250
Low
55.00
Averages
62.00
High
69.00
Wells Fargo
Michael Sison
Equal Weight
maintain
$52 -> $55
2025-11-12
Reason
Wells Fargo
Michael Sison
Price Target
$52 -> $55
2025-11-12
maintain
Equal Weight
Reason
Wells Fargo analyst Michael Sison raised the firm's price target on Ingevity to $55 from $52 and keeps an Equal Weight rating on the shares. The firm continues to await a more robust recovery in the global auto market, which remains uncertain.
BMO Capital
Outperform
maintain
$62 -> $68
2025-09-05
Reason
BMO Capital
Price Target
$62 -> $68
2025-09-05
maintain
Outperform
Reason
BMO Capital raised the firm's price target on Ingevity to $68 from $62 and keeps an Outperform rating on the shares. The company announced the sale of its CTO Refinery and most of the InSpec business in its Performance Chems platform for a solid high-teens multiple, and the firm sees this reducing earnings volatility and improving the margin profile of the business, the analyst tells investors in a research note.
BMO Capital
John McNulty
Outperform
maintain
$56 -> $62
2025-08-07
Reason
BMO Capital
John McNulty
Price Target
$56 -> $62
2025-08-07
maintain
Outperform
Reason
BMO Capital analyst John McNulty raised the firm's price target on Ingevity to $62 from $56 and keeps an Outperform rating on the shares after its Q2 earnings beat. Despite the solid 21% jump in the stock, the firm sees significant upside ahead for Ingevity as it has reached the inflection point in its earnings and free cash flow, the analyst tells investors in a research note.
Wells Fargo
Michael Sison
Hold
Maintains
$45 → $32
2025-04-09
Reason
Wells Fargo
Michael Sison
Price Target
$45 → $32
2025-04-09
Maintains
Hold
Reason
Wells Fargo lowered the firm's price target on Ingevity to $32 from $45 and keeps an Equal Weight rating on the shares. Given increased risks in a post tariff world, the firm recommends a more defensive position within the chemicals sector into Q1 2025 results as Wells expects cautious outlook commentary.
BMO Capital
John McNulty
Hold
to
Buy
Upgrades
$62 → $65
2025-02-26
Reason
BMO Capital
John McNulty
Price Target
$62 → $65
2025-02-26
Upgrades
Hold
to
Buy
Reason
BMO Capital analyst John McNulty raised the firm's price target on Ingevity to $62 from $61 and keeps a Market Perform rating on the shares after its Q4 earnings beat. The company is starting to reap the benefits of roughly two years of work to escape the pressures of its CTO - Crude Tall Oil - platform, the analyst tells investors in a research note. Ingevity is also seeing its high value add Performance Materials business enjoying growth despite muted end-market volumes, BMO adds.
BMO Capital
John McNulty
Hold
Maintains
$61 → $62
2025-02-20
Reason
BMO Capital
John McNulty
Price Target
$61 → $62
2025-02-20
Maintains
Hold
Reason
BMO Capital analyst John McNulty raised the firm's price target on Ingevity to $62 from $61 and keeps a Market Perform rating on the shares after its Q4 earnings beat. The company is starting to reap the benefits of roughly two years of work to escape the pressures of its CTO - Crude Tall Oil - platform, the analyst tells investors in a research note. Ingevity is also seeing its high value add Performance Materials business enjoying growth despite muted end-market volumes, BMO adds.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Ingevity Corp (NGVT.N) is 10.83, compared to its 5-year average forward P/E of 13.13. For a more detailed relative valuation and DCF analysis to assess Ingevity Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
13.13
Current PE
10.83
Overvalued PE
16.43
Undervalued PE
9.82
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
8.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.74
Undervalued EV/EBITDA
7.45
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.51
Current PS
0.00
Overvalued PS
1.98
Undervalued PS
1.03
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
NGVT News & Events
Events Timeline
(ET)
2025-11-11
07:31:34
Ingevity secures licensing for nanotube manufacturing technology for electric vehicle batteries.
2025-11-05 (ET)
2025-11-05
17:21:57
Ingevity projects FY25 revenue between $1.25B and $1.35B, with consensus at $1.28B
2025-11-05
17:20:44
Ingevity announces Q3 adjusted EPS of $1.52, surpassing consensus estimate of $1.39
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
7.5
11-11NewsfilterCHASM and Ingevity Strengthen Partnership with Licensing Agreement to Ensure Local CNT Supply Chain for EV Battery Gigafactories in North America and Europe
Preview
5.0
10-23NewsfilterIngevity appoints Ruth Castillo as senior vice president and head of Performance Materials
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/b9f80f29e0c7bbf53d49262f5b2de50d15e1fd343fe9b1f979afa087019de5d4.jpg)
Preview
3.0
09-24NASDAQ.COMProjected Target Price for IJS Analyst: $122
Sign Up For More News
People Also Watch
FAQ
What is Ingevity Corp (NGVT) stock price today?
What is Ingevity Corp (NGVT)'s business?
What is the price predicton of NGVT Stock?
What is Ingevity Corp (NGVT)'s revenue for the last quarter?
What is Ingevity Corp (NGVT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Ingevity Corp (NGVT)'s fundamentals?
How many employees does Ingevity Corp (NGVT). have?